Better Together: A Mixed-Methods Study of Palliative Care Co-Management for Patients with Interstitial Lung Disease

Bischoff, Kara; Choi, Sylvia; Su, Anny; Cohen, Eve; Oettel, Elida; Blachman, Marsha; Meister, Sarah; Zapata, Carly; Lindenfeld, Paul; Calton, Brook; Witt, Leah J.; Pantilat, Steven Z.; Shah, Rupal J.

doi:10.1089/jpm.2020.0787

Cited by 15 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A palliative care-ILD collaborative care pilot programme to improve access to palliative care found that with telehealth delivery of palliative care, completion of advance care planning notes increased to 100% with increased discussion and completion of advanced directives. Qualitative interviews with patients found benefits with the palliative care team that was patient-centred, improved symptoms and medication management, and better understanding of illness and all patients and caregivers interviewed agreed that palliative care was very beneficial [29 ▪▪ ].…”

Section: Primary Studies Of Interventions For Caregivers Of Patients ...mentioning

confidence: 99%

“…This study on caregivers of patients with cancer was included, as the diseases are both serious illnesses and have similar disease course trajectories. Three studies included face-to-face interviews [25 ▪▪ –27 ▪▪ ], and two were intervention studies [28 ▪▪ ,29 ▪▪ ]. The remaining seven articles sought input from healthcare professionals and researchers who care for patients with pulmonary fibrosis.…”

Section: Review Papersmentioning

confidence: 99%

See 1 more Smart Citation

A scoping review of unmet needs of caregivers of patients with pulmonary fibrosis

Klein

Logan

Lindell

2021

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

Section: Primary Studies Of Interventions For Caregivers Of Patients ...mentioning

confidence: 99%

Section: Review Papersmentioning

confidence: 99%

A scoping review of unmet needs of caregivers of patients with pulmonary fibrosis

Klein

Logan

Lindell

2021

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

“…In nonmalignant pulmonary diseases, receiving palliative care is associated with better symptom relief and quality of life, increased rate of advance care planning, death outside the hospital, and decreased burden from futile therapies and investigations in end of life. 3 , 10 , 18 , 19 , 27–30 The symptom burden and the need of palliative care in different nonmalignant pulmonary diseases are similar but the disease trajectory varies. 31 , 32 Patients with COPD may live long with advanced disease and severe breathlessness, whereas survival time is typically shorter among patients with end-stage ILD.…”

Section: Discussionmentioning

confidence: 99%

“…Similar to a study conducted by Bischoff et al, we found that including a palliative care consultation increased the amount of advance care planning notes and reported decisions to withhold futile therapies. 27 …”

Section: Discussionmentioning

confidence: 99%

Specialist Palliative Care Consultation for Patients with Nonmalignant Pulmonary Diseases: A Retrospective Study

Pihlaja

Rantala

Leivo-Korpela

et al. 2023

Palliative Medicine Reports

View full text Add to dashboard Cite

Background: Few patients with chronic nonmalignant pulmonary diseases receive specialist palliative care consultation, despite their high symptom burden in end of life. Objectives: To study palliative care decision making, survival, and hospital resource usage in patients with nonmalignant pulmonary diseases with or without a specialist palliative care consultation. Methods: A retrospective chart review of all patients with a chronic nonmalignant pulmonary disease and a palliative care decision (palliative goal of therapy), who were treated in Tampere University Hospital, Finland, between January 1, 2018 and December 31, 2020. Results: A total of 107 patients were included in the study, 62 (58%) had chronic obstructive pulmonary disease (COPD), and 43 (40%) interstitial lung disease (ILD). Median survival after palliative care decision was shorter in patients with ILD than in patients with COPD (59 vs. 213 days, p = 0.004). Involvement of a palliative care specialist in the decision making was not associated with the survival. Patients with COPD who received palliative care consultation visited less often emergency room (73% vs. 100%, p = 0.019) and spent fewer days in the hospital (7 vs. 18 days, p = 0.007) during the last year of life. When a palliative care specialist attended the decision making, the presence and opinions of the patients were recorded more often, and the patients were more frequently referred to a palliative care pathway. Conclusions: Specialist palliative care consultation seems to enable better end-of-life care and supports shared decision making for patients with nonmalignant pulmonary diseases. Therefore, palliative care consultations should be utilized in nonmalignant pulmonary diseases preferably before the last days of life.

show abstract

“…Upskilling and training of ILD/chronic disease teams in the provision of palliative care should also be improved. Evidence demonstrates that a multi‐disciplinary approach to the provision of palliative care improves uptake of advanced care planning and certain approaches may also improve quality of life 223,246,252,253 . There is increasing evidence that ILD nurse‐led palliative care models are feasible and effective in supporting both the patients and their care givers 254,255 …”

Section: Non‐pharmacological Therapymentioning

confidence: 99%

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Mackintosh,

Keir,

Troy

et al. 2024

Respirology

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.

show abstract

Better Together: A Mixed-Methods Study of Palliative Care Co-Management for Patients with Interstitial Lung Disease

Cited by 15 publications

References 19 publications

A scoping review of unmet needs of caregivers of patients with pulmonary fibrosis

A scoping review of unmet needs of caregivers of patients with pulmonary fibrosis

Specialist Palliative Care Consultation for Patients with Nonmalignant Pulmonary Diseases: A Retrospective Study

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Contact Info

Product

Resources

About